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ABSTRACT

Standard treatment protocols for high- grade gliomas, such as glioblastoma
multiforme (GBM), are highly ineffective due to their inability to eradicate infiltrating
tumor cells. Improvements in overall survival are likely to be realized only with the
development of more effective localized therapies capable of eradicating tumor cells in
the surgical resection margin and beyond. Photochemical internalization (PCI) is a
localized light-based therapeutic modality that enhances the efficacy of therapeutic
macromolecules including chemotherapeutic agents such as bleomycin. A number of
studies have shown that this photodynamic therapy (PDT) - based modality may prove
effective in the treatment of high- grade gliomas.
Three-dimensional multicell human glioma spheroids were used as a tumor model to
investigate the efficacy of combination therapies consisting of hyperthermia and PCI.
Hyperthermia has been shown to increase the efficacy of a number of therapies including
radiation and chemotherapy, however, there have been no studies investigating its utility
in combination with PCI.
The results show that hyperthermia and PCI interact in a synergistic manner over a
very narrow range of light and temperature levels. In this tumor model, temperatures of
45 o C resulted in total spheroid death: the exact hyperthermic threshold was estimated to
be between 42 and 45 o C which provided the rationale for the temperature range
investigated (40 – 42 o C). No significant differences in growth kinetics and survival were
observed between PCI- and PDT -exposed spheroids at radiant exposures < 1.5 J cm-2 . In
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contrast, all PDT and PCI spheroids irradiated with 3.0 J cm-2 died, suggesting that the
useful light range is between 1.5 and 3.0 J cm-2 .
A relatively low level of synergism was observed between PCI and hyperthermia
at 1.5 J cm-2 and 40 o C, while a high degree of synergism was found when the two
modalities were combined at a light level of 2.5 J cm-2 and a temperature of 42 o C. This is
the first observation of a synergistic interaction between PCI and hyperthermia and,
collectively, the results provide the rationale for additional studies in animal brain tumor
models.

iv

ACKNOWLEDGMENTS

This research project would not have been realized without the gracious support
of so many people. I would first like to thank my advisor, Dr. Steen Madsen, he always
gave me guidance and excellent advice during my study and research here at UNLV.

I wish to extend my thanks to the thesis committee members, Dr. Ralf Sudowe,
Dr. Janet Dufek, and Dr. Gary Cerefice. I am honored to have this group of scientists in
my committee.

Special thanks are also in order for the wonderful support of Van Vo, Mary
Turner, and Doris Coomes during the course of my research and studies at UNLV.

I would finally like to express my gratitude to all my friends and family. Thank
you to my parents, for all your support and encouragement over the years. I’d especially
like to thank my husband, Mike, for always supporting me after a long day in the
laboratory.

v

TABLE OF CONTENTS
ABSTRACT....................................................................................................................... iii
ACKNOWLEDGMENTS ................................................................................................... v
LIST OF FIGURES .......................................................................................................... vii
CHAPTER 1
INTRODUCTION .................................................................................1
1.1 Malignant Brain Tumor ........................................................................................1
1.2 Glioblastoma .........................................................................................................3
1.3 Photodynamic Therapy .........................................................................................5
1.4 Photochemical Internalization...............................................................................7
1.5 Bleomycin ...........................................................................................................11
1.6 Hyperthermia ......................................................................................................13
1.7 Multicellular Tumor Spheroids ...........................................................................16
1.8 Scope of study .....................................................................................................18
CHAPTER 2
MATERIALS AND METHODS.........................................................19
2.1 Cell line .............................................................................................................19
2.2 Spheroid Growth .................................................................................................20
2.3 PDT and PCI Treatments ....................................................................................20
2.4 Hyperthermia ......................................................................................................21
2.5 Statistical Analysis ..............................................................................................21
CHAPTER 3
RESULTS ............................................................................................23
3.1 Radiant exposure of 0.5J cm-2 ............................................................................23
3.1.1 37˚C and 50˚C ....................................................................................................23
3.1.2 40˚C and 45˚C ....................................................................................................26
3.1.3 42˚C
..............................................................................................................27
3.2 Radiant exposure of 1.0 J cm-2 ...........................................................................28
3.3 Radiant exposure of 1.5 J cm-2 ...........................................................................29
3.4 Radiant exposure of 2.5 J cm-2 ...........................................................................31
3.5 Radiant exposure of 3.0 J cm-2 ...........................................................................33
CHAPTER 4

DISCUSSION ......................................................................................34

CHAPTER 5

CONCLUSIONS..................................................................................39

APPENDIX: LIST OF EQUATIONS ...............................................................................41
REFERENCES ..................................................................................................................42
VITA

..............................................................................................................47

vi

LIST OF FIGURES
1

Age-Specific Incidence of Primary Brain and CNS Tumors.

2

2

Distribution of all primary brain and CNS gliomas.

2

3

Jablonski Diagram.

6

4

Photochemical reaction pathways from the triplet state of photosensitizer.

5

Endocytic vesicle undergoing PCI.

8

6

Illustration of PCI.

9

7

Chemical Structure of AlPcS 2a.

10

8

Structure of bleomycin.

12

9

Cell death in multicellular tumor spheroids.

16

10

Average spheroid volume at 37˚C for control groups.

24

11

Average spheroid volume at 37˚C and 50˚C.

25

12

Average spheroid volume for control groups at 40 and 45˚C.

26

13

Average spheroid volume at 40 and 45˚C.

27

14

Average spheroid volume at 42˚C.

28

15

Average spheroid volume for 1J cm-2 at 37 and 42˚C.

28

16

The percentage of viable spheroids at 40˚C.

29

17

Average spheroid volume at 1.5J cm-2 for 37˚C and 40˚C.

30

18

The percentage of viable spheroids at 2.5J cm-2 for 37˚C and 42˚C.

31

19

Average spheroid volume at 2.5J cm-2 for 37˚C.

32

20

Average spheroid volume at 2.5J cm-2 for 42˚C.

32

21

Average spheroid volume at 3J cm-2 for 37, 40, and 42˚C.

33

vii

7

CHAPTER 1

INTRODUCTION
1.1 Malignant Brain Tumors
Primary malignant brain tumors are uncommon and represent 2 percent of all
adult cancers in the United States [Iacob 2009]. Gliomas are a non-uniform group of
tumors in the central nervous system (CNS). They can be classified as astrocytomas,
ependymomas, and oligodendrogliomas. Astrocytomas are the most common and are
classified as low-grade, while anaplastic astrocytomas and glioblastomas are considered
grades III and IV, respectively [Iacob 2009]. The most common type is glioblastoma
multiforme (GBM) which has a dismal prognosis. Although a number of causes have
been suggested (electromagnetic fields, cellular phones, head trauma, pesticides, Nnitroso compounds in food products such as cheese and fish, and genetic syndromes), the
only proven risk factor for the development of GBM is exposure to high dose ionizing
radiation [Chandana 2008]. Common symptoms include nausea, vomiting, headaches,
seizures, personality changes, and neurocognitive deficit. The American Cancer Society
estimates there are 12,000 deaths per year in the United States due to brain and nervous
system cancers. As shown in Figure 1, the occurrence of primary brain tumors is highest
between the ages of 65 and 79 years with a slightly higher frequency in men [Chandana
2008].
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Figure 1.

Age-Specific Incidence of Primary Brain and CNS Tumors by Selected

Histologies; collected 2004-2007. (Adapted from CBTRUS 2011)

Of the estimated 51,000 primary brain tumors diagnosed in the United States
every year, 36 percent are gliomas. Approximately 50% of gliomas are GBM (Figure 2)
[Clarke 2010].

Figure 2. Distribution of all primary brain and CNS gliomas by histology subtypes;
collected 2004-2007. (Adapted from CBTRUS 2011)
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1.2 Glioblastoma
Starting in 2005, the standard treatment therapy for GBM consists of surgical
resection followed by chemotherapy with temozolomide and radiation up to 60 Gy.
Temozolomide (TMZ) is an alkylating agent that attaches an alkyl group to DNA
resulting in irreparable damage. The median survival for patients receiving this treatment
regimen is 14.6 months compared to 12.1 months for patients treated with radiation only
[Pan 2011].

Even with the combined treatments, the disease almost always recurs

[Nishikawa 2010]. In many cases, the complete removal of a glioma is not possible due
to extensive tumor cell infiltration into normal brain. The aim of current treatment
regimens is to eliminate these infiltrative cells [Iacob 2009].
Diagnosing a brain tumor starts with imaging, followed by histopathology to
verify the diagnosis. Recent advances in brain imaging techniques have resulted in
improved tumor localization and evaluation of functional status.
commonly used to determine treatment outcome.

Imaging is also

Gadolinium-enhanced magnetic

resonance imaging (MRI) is the recommended method for the initial anatomic assessment
of brain lesions. MRI is preferred to computed tomography because of its superior soft
tissue contrast which allows for more accurate assessments of lesions in the spine,
brainstem, and cerebellum. Magnetic resonance spectroscopy can also be used to provide
metabolic and biochemical information about the tumor. By pinpointing the cortical
regions that control language, memory, and motor functions, functional MRI can be used
for neurosurgical planning and neurologic risk evaluation. Positron emission tomography
(PET) is an important tool for evaluating the aggressiveness of the tumor and locating
highly metabolic areas within the tumor. PET can also be used during the follow-up
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phase to evaluate the efficacy of treatment and to delineate tumor recurrence from
radiation- induced necrosis.
A biopsy of the tumor tissue will determine the diagnosis and the type of
treatment required. The choice to perform complete tumor resection depends on the
location of the tumor. Complete resection is possible for some tumor types, however, the
situation is complicated for high- grade gliomas such as GBM since tumor cells tend to
migrate into the normal brain where they cannot be detected with current clinical imaging
modalities. Since these cells are responsible for tumor recurrence, efforts must be devoted
to find therapeutic approaches to eradicate these highly infiltrative cells. To that end, a
number of local therapies, including photodynamic therapy (PDT) and photochemical
internalization (PCI) have been proposed.
After surgery, the standard treatment of high grade gliomas calls for external or
internal radiation including highly conformal techniques such as stereotactic radiosurgery. Despite significant advances in radiation delivery devices, allowing for highly
conformal treatments (and dose escalation), high-dose radiotherapy has had minimal
impact on overall survival. This is probably due to the infiltrative nature of glioma cells,
i.e., many of these cells have migrated into normal brain where the radiation dose is
insufficient to eradicate them and hence, they form the locus of new tumors.
Delivery of drugs to the brain is complicated by the presence of the blood-brain
barrier (BBB) which prevents most therapeutic agents (including chemotherapeutic
compounds) from entering the brain. This poses a significant challenge for the
eradication of infiltrating tumor cells. A number of different delivery methods have been
attempted in order to address the difficulties posed by the BBB. For example, drug-
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containing wafers have been placed in the surgical cavity after tumor removal and used in
combination with radiation therapy. Convection-enhanced delivery (CED) approaches
have also been attempted.

Typically, CED uses multiple catheters implanted in the

resection cavity following tumor removal. The chemotherapeutic agent is introduced into
the resection cavity and brain adjacent to tumor via positive pressure infusion [Clarke
2010]. The recent introduction of the chemotherapeutic agent, temozolomide, represents
a significant development in the treatment of GBM since this drug has been shown to
prolong overall survival by 2-3 months [Fadul 2008]. Due to its small molecular weight,
TMZ efficiently crosses the BBB without significant adverse effects [Koukourakis 2009].
Due to the lack of efficacy of current GBM treatments, a wide variety of
investigational therapies are currently being evaluated in both pre-clinical and clinical
studies. For example, PDT is a localized laser-based treatment approach that has shown
promise for the eradication of infiltrating glioma cells within a few cm of the resection
margin [Mathews 2009].

1.3 Photodynamic Therapy
PDT is based, in part, on the observation that photosensitizers show preferential
accumulation in tumor cells. Light absorption at resonant wavelengths results in
photosensitizer excitation and subsequent cytotoxicity. Cytotoxicity is predominantly
caused by a singlet oxygen- mediated reaction that causes damage to enzymes, plasma
membranes, and cytoplasmic or nuclear organelles. PDT dosimetry is complex as it
depends on a number of parameters including photosensitizer concentration, light dose,
dose rate, and oxygen concentration [Dubessy 2000]. A threshold dose is required in
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order to induce cytotoxicity and this may be difficult to achieve in vivo due to a number
of factors including limited light penetration in biological tissues and inadequate oxygen
and photosensitizer concentrations in tumor tissues [Hogset 2004].
PDT is initiated with the absorption of light by a photosensitizer which results in a
transition to an electronically excited singlet state (Figure 3) [Berg 2005]. De-excitation
to the ground state occurs with high probability and results in prompt emission of
fluorescence. De-excitation to a triplet state via inter-system crossing occurs with low
probability. The triplet photosensitizer can de-excite via type I or II mechanisms (Figure
4). For the vast majority of photosensitizers, deactivation occurs primarily via a type II
mechanism in which the excited triplet state sensitizer interacts with ground state triplet
molecular oxygen resulting in the generation of singlet molecular oxygen – a strong
oxidizing agent capable of causing significant damage to amino acids, unsaturated fatty
acids, cholesterol, and guanine [Berg 2005].

Figure 3. Jablonski diagram showing electronic states following absorption of
light by a photosensitizer [Berg 2005].
6

Figure 4. Photochemical reaction pathways from the triplet state of a photosensitizer
[Berg 2005].

Since singlet oxygen has a range of < 20 nm, the intended target must be close to
the excited photosensitizer in order to be affected [Hogset 2004]. A good photosensitizer
should have a high probability of triplet formation and the triplet state should be longlived in order to react with neighboring molecules [Berg 2005].

Depending on the

photosensitizer and cell line, the photodynamic effects will lead to apoptosis, necrosis, or
autophagy [Gupta 2010].

1.4 Photochemical Internalization
PCI is designed to improve the use of macromolecules in cancer therapy in
a site-specific manner [Dietze 2005]. The technique is summarized in Figures 5 and 6.
PCI is a special version of PDT in which a plasma membrane localizing photosensitizer
7

and a macromolecule (e.g. bleomycin) is localized in endocytic vesicles of target cells
(e.g. infiltrating glioma cells).

Figure 5. An endocytic vesicle containing a photosensitizer and macromolecule
undergoing PCI. When light is incident on the vesicle, reactive oxygen species are
formed, the membrane is broken and the macromolecule is released into the cytosol, but
only in the irradiated area [Hogset 2004].
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Figure 6. Illustration of PCI. A: Drugs enter cells via endocytosis and are
transported to lysosomes where they are eventually degraded before serving their
function. B: Photosensitizer accumulates on endosome membranes and light exposure
causes the membrane to rupture thus releasing the drug into the cytosol where it is free to
diffuse to the target [Weyergang 2011].

Photosensitizers used in PCI must have a strong affinity for the plasma
membrane. Such compounds will be incorporated into the membranes of endosomes and,
following light activation, will result in the disruption of the membrane and subsequent
release of the contents of the endosome. The photosensitizer must be excluded from the
endosome interior in order to prevent damage to the contents of the endosome [Hogset
2004].
Aluminum phthalocyanine disulfonate (AlPcS 2a)

is the

most common

photosensitizer used in PCI (Figure 7). Photosensitizers are characterized by their
structure. The efficiency and localization within the cell depends on how their polar and
hydrophobic chains are distributed.
9

Figure 7. The chemical structure of aluminum phthalocyanine disulfonate (AlPcS 2a) with
two sulfonate groups on adjacent rings [Hogset 2004].

AlPcS2a is a second generation amphiphilic photosensitizer with both hydrophilic
and lipophilic domains [Bonneau 2004] and, as such, has excellent membrane penetrating
properties, and high phototoxicity [Peng 1990]. Sulphonated aluminum phthalocyanine
sensitizers are useful in PDT because of their stronger absorption at longer wavelengths
of 650-800 nm [Ambroz 1990] where light penetration in biological tissues is optimal.
Typically, the 670 nm absorption resonance is used in PCI applications. Additionally,
AlPcS2a has low absorption at other wavelengths, thus reducing the potential for skin
photosensitivity [Gupta 2010].
The rapid attenuation of light in most tissues, including the brain, should lead to
minimal side effects since the effect is localized to the irradiated area. The endosomal
escape of macromolecules including genes, oligonucleotides and proteins by means of
PCI has been documented both in vitro and in vivo and has been shown to increase the
therapeutic effect in a synergistic manner [Dietze 2005, Selbo 2000]. Compared to other
drugs, macromolecules (e.g. nucleic acids, peptides, proteins, and synthetic polymers) are
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very specific when it comes to targeting [Hogset 2004].

The delivery of these

macromolecules to targets within the cell is often problematic since their associated
delivery vehicle (the endosome) is often degraded in lysosomes. Therefore, the
macromolecules are often destroyed prior to reaching their target (e.g. the DNA in the
nucleus). PCI solves this problem by releasing the macromolecules from the endosome
prior to lysosomal degradation [Berg 2007].
One benefit of using PCI is that there are no size restrictions for the delivery of
molecules, such as chemotherapeutic agents [Hogset 2004].

PCI releases drugs that

normally would be degraded in lysosomes thereby increasing the efficacy of the agent.
Consequently, lower doses may be used thus minimizing the probability of adverse
effects to the patient [Weyergang 2011]. PCI is limited by the penetration depth of light
in biological tissues. For example, the penetration depth (e -1 intensity) of 670 nm light in
brain tissues is approximately 2 mm. However, the low light fluences required for the
PCI effect suggest that treatment depths of 1-2 cm should be possible [Hogset 2004].
This is significant since the majority of GBM tumors recur within 2 cm of the resection
cavity [Wallner 1989].

1.5 Bleomycin
Bleomycin (BLM) is a 1.5 kDa glycopeptic antibiotic that has been used in a
number of chemotherapeutic regimens for the treatment of a variety of cancers including,
squamous cell carcinomas of the head and neck, esophagus, bronchus, and skin, as well
as Hodgkin’s and non-Hodgkin’s lymphoma [Dietze 2005]. BLM is water-soluble and
was discovered in 1966 by Hamao Umezawa [Umezawa 1966]. BLM was originally
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used as copper complexes from streptomyces verticillus [Roy 1984]. BLM has been used
in brain tumor treatments since the early 1970’s and is delivered directly to the tumor
since it does not pass through the intact BBB [Linnert 2009]. BLM is a mixture of eleven
molecules that differ in their terminal amine part, which is involved in nucleic acid
interactions. BLM also has a glycannic part, a bithiazole moiety that binds to the DNA,
and a pseudopeptidic area that binds transition metals and is used in sequence recognition
(Figure 8) [Mir 1996].

Figure 8. The structure of bleomycin [Stubbe 1986].

The molecule exerts its toxic effects by causing single and double-strand DNA
breaks [Zaniboni 2005, Roy 1984]. Bleomycin induces single-strand and double-strand
DNA breaks with a 10:1 ratio resulting in cell arrest in the G2-M phase. In order to
create these effects, BLM must pass through the cellular membrane and diffuse to the
nucleus [Stubbe 1986].
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BLM has a high intrinsic cytotoxicity, but since it cannot diffuse through the cell
membrane, its capabilities are limited [Mir 1996]. Due to the limited penetration of BLM
through the plasma membrane, tumor cells have a relatively low sensitivity to this anticancer agent.

BLM enters cells via receptor- mediated endocytosis resulting in its

encapsulation in endosomes.

Once in the cytosol, most endosomes end up in the

lysosomes along with their contents (bleomycin). Therefore, the vast majority of BLM
never reaches the DNA [Pron 1999]. Due to its poor efficacy, BLM is typically used in
combination with other agents [Mir 1996].

1.6 Hyperthermia
As a therapeutic procedure, hyperthermia produces elevated tissue temperatures
resulting in impairment of cellular function. Specifically, increased temperatures affect
enzymatic and structural function within the cells. This can affect cell growth, and lead
to cell death via apoptosis and necrosis, depending on the temperature [Van der Zee
2002].

Hyperthermia causes changes in the cell membrane that can reduce

transmembrane transport and

destabilize the cell’s potential [Dereski 1995].

Additionally, hyperthermia can result in inhibition of nucleic acid synthesis, and enzyme
repair, and changes in DNA conformality [Van der Zee 2002].

From a therapeutic

perspective, tumor cells are less resistant to sudden increases in temperature than normal
cells.
Temperature increases can be achieved by different techniques including
microwaves, radiofrequency, ultrasound, or electrically- induced methods. All of these
approaches have yielded good results, but there is still the problem of obtaining
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homogeneous temperature distributions throughout large tumors.

Failure to achieve

adequate temperature elevations throughout the tumor results in recurrence, whereas
overheating can result in undesirable inflammatory responses [Silva 2011]. Superficial
tumors are excellent candidates for hyperthermia since they can be treated noninvasively
via surface irradiation [Zhao 2011].
Heat therapy has been used for twenty years and has been shown to result in local
control for a number of tumor types [Zhao 2011]. Hyperthermia has been used alone and
in combination with other treatments [Dereski 1995]. Hyperthermia-induced cytotoxicity
depends on both temperature and heating time. Hyperthermia occurs at temperatures
between 40 and 44˚C, which is cytotoxic for tumor cells due to insufficient blood
perfusion via the tumor vasculature [Van der Zee 2002].

For optimum effect, the

elevated temperatures are typically maintained over a period ranging from 30 to 60 min.
Due to impaired blood flow, tumors have reduced thermoregulatory abilities resulting in
preferential heating during hyperthermia. Furthermore, reduced blood flow results in
deprivation of oxygen and nutrients to tumors making them more heat sensitive [Field
1979]. Hyperthermia is a strong sensitizer of radiotherapy and a number of cytotoxic
drugs: combination therapies consisting of hyperthermia and radiotherapy or
chemotherapy have been shown to produce additive effects, as long as the treatments are
administered without a significant time gap. Hyperthermia likely enhances the effects of
chemotherapy by increasing tumor perfusion resulting in increased drug delivery [Van
der Zee 2002].
The limiting factor in chemotherapeutic treatment regimens is drug toxicity.
Previous experiments with murine tumors have shown positive results by using radiation,
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chemotherapy, and hyperthermia in different combinations. For example, hyperthermia
in combination with bleomycin increased cell death and tumor regression [Rao 2010].
The chemotherapy-hyperthermia combination has also shown improvement of survival
rates and quality of life in patients [Zhao 2011]. Previous studies have shown that
exposing cells to high temperatures can alter the fluidity of the cellular membrane and
inhibit protein synthesis. Hyperthermia can also destroy enzymes involved in DNA
synthesis and cause cytotoxic effects. These effects can lead to structural alterations in
biological macromolecules, increase oxygen concentrations in the cell, affect material
transport, and alter energy conversion. Many studies have also shown that hyperthermia
leads to apoptosis [Zhao 2011].
PDT has been used in combination with hyperthermia both in vivo and in vitro.
For example, Dereski et al (1995) found that the effects were greater than additive when
hyperthermia was given post-PDT. Hyperthermic temperatures were found to inhibit
repair of sub- lethal damage thereby making hypoxic cells more sensitive to PDT. Using
a murine mammary adenocarcinoma model, Chen et al (1996) showed that the
combination of PDT and hyperthermia produced a synergetic tumor response.
Hirschberg et al, (2004) examined synergistic effects of 5-aminolevulinic acid- mediated
PDT and hyperthermia concurrently on human and rat glioma spheroids.

The results

showed that, when administered separately, PDT and hyperthermia were not very
effective, however, concurrent administration of the two treatment modalities resulted in
significant toxicity.
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1.7 Multicellular Tumor Spheroids
A spheroid is an in vitro tumor model that has some characteristics of in vivo
tumors [Dubessy 2000]. Multicellular tumor spheroids (MCTS) are three-dimensional
collection of cells that mimic small tumors and metastases.

MCTS have cellular

heterogeneity which is a property of most solid tumors [Mueller-Klieser 2000]. The
biological behavior of spheroids and their shape are similar to tumor nodules and they are
therefore more representative of an in vivo situation than monolayer cell cultures. MCTS
represent an excellent model for the initial evaluation of experimental therapies
[Hirschberg 2004].
Spheroids are formed from the aggregation of multiple clonogenic cells. The
cells proliferate exponentially and are weakly bound together. After a few hours, a
critical cell density is reached and the spheroid becomes reinforced by intercellular links
such as gap junctions and desmosomes [Dubessy 2000].

Figure 9. The pathway spheroids undergo when cells move from the viable outer surface
to the necrotic center and cell death [Mueller-Klieser 2000].

16

As illustrated in Figure 9, cells are stratified into three layers according to
oxygen, pH and nutrient gradients: an outer proliferative layer that is in contact with a
nutrient-rich medium, a non-proliferative layer lacking in oxygen and nutrients and a
necrotic core consisting of dead cells. Due to the limited diffusion of oxygen and
nutrients, a necrotic core develops when the spheroid reaches a diameter of 200-500 µm.
[Dubessy 2000].

Since MCTS are cultured from genetically stable cell lines, the

structure can be reproduced. This allows for reproducibility of growth kinetics, diameter
of the necrotic center, and viable rim of cells over multiple experiments. The necrotic
core typically grows at a similar rate as the viable outer surface [Mueller-Klieser 2000].
The size of necrosis varies by spheroid diameter, cell line, oxyge n gradient, pH, and
nutrients [Dubessy 2000]. Spheroid viability can be determined by measuring its volume
or by measuring the necrotic center or viable rim thickness.
The ability of spheroids to mimic oxygen gradients found in tumor nodules in
vivo makes them ideally suited for investigational studies involving oxygen-dependent
therapies such as PDT and ionizing radiation. In this respect, the non-proliferating
quiescent cells in hypoxic regions of spheroids are particularly relevant since they
represent a cell population resistant to oxygen-dependent therapies. The efficacy of a
therapy is critically dependent on its ability to eradicate these cells. The primary
disadvantage of MCTS is their inability to model tumor vasculature. Additionally, MCTS
lack the cellular heterogeneity of tumors in vivo as well as a functioning immune system
[Madsen 2006].
Not surprisingly, studies show that MCTS are less sensitive to PDT than
monolayers. As the size of the spheroid increases, the sensitivity to PDT decreases.
17

These observations can be explained in terms of oxygen availability. For example, cells
in monolayers are well oxygenated whereas a significant fraction of cells in spheroids are
located in hypoxic areas and therefore exhibit an increased resistance to oxygen- mediated
therapies such as PDT. Uneven photosensitizer distributions in spheroids are also a
contributing factor to their increased PDT resistance compared to monolayers [Dubessy
2000].

1.8 Scope of Study
The overall objective of the proposed work is to determine whether hyperthermia
increases the efficacy of PCI-mediated delivery of bleomycin in an in vitro model
consisting of human glioma spheroids. It is hypothesized that PCI, performed under
hyperthermic conditions, will increase the efficacy of bleomycin as determined from
spheroid survival and growth kinetics. Furthermore, it is hypothesized that, under
appropriate light irradiation and temperature levels, the interaction between PCI and
hyperthermia is synergistic rather than additive.
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CHAPTER 2

MATERIALS AND METHODS

2.1 Cell Line
All cell line manipulations were performed in a Labconco Purifier Class A2
Biological Safety Cabinet at the University of Nevada, Las Vegas. The human glioma
cell line (ACBT; University of California, Irvine) was obtained from biopsy. Cells were
incubated at 37˚C, 5.0% CO 2 , and 95% humidity inside a Shell Lab CO 2 Series incubator.
The cell line was kept in Gibco Dulbecco’s Modified Eagle Medium (DMEM) High
Glucose 1X with 10% heat- inactivated fetal bovine serum (FBS), 25mM HEPES buffer
(pH 7.4), penicillin (100U/ml), and streptomycin (100 µg/mL). The monolayer cells
were passed twice a week using the same procedure. The confluency of the flask was
noted prior to washing with 5mL of Gibco phosphate buffered saline (PBS) with pH of
7.2 and emptied of any remaining media. Next, 1 mL of Gibco 0.25% Trypsin-EDTA
was added to the flask and left to sit for 5 minutes. Trypsin is a proteolytic enzyme that
allows the ACBT cells to detach from the bottom of the flask. After 5 minutes, the flask
was tapped against the lab cabinet to help detach any cells remaining in the flask. Then,
4 mL of DMEM was added to the flask and pipetted up and down and transferred to a 15
mL centrifuge tube. In order to maintain the cell line, 500 uL was added to 4.5 mL of
DMEM in a new flask and the whole process was repeated.
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2.2 Spheroid formation
Spheroids were formed using a modified centrifugation method first described by
Ivascu and Kubbies [2006]. Briefly, 5,000 ACBT cells were detached from the growth
flask; the exact number of cells was determined from coulter counting. The cells were
pipetted into one well of a 96-well plate. Each round bottomed well was coated with
matrigel and the plate was centrifuged at 1000g for 10 min. Following centrifugation, the
well plate was placed in a CO 2 incubator for 48 h to allow them to take on the usual 3dimensional spheroid morphology.
2.3 PDT and PCI treatments
After 48 hours, the resultant 350-400 µm diameter spheroids were transferred
from the 96-well plate to 35 mm irradiation dishes where they were incubated in 1 µg/mL
AlPcS2a for 18 h at 37 o C and 5% CO2 . Following incubation, spheroids were washed
and placed into new medium. Spheroids in the PCI group were then subjected to an
additional incubation in 0.25 µg/mL of bleomycin for 4 h. Following incubation,
spheroids in both PDT and PCI groups were irradiated with a photodiode laser
(wavelength = 670 nm) coupled to a 200 µm diameter optical fiber fitted with a microlens. In all cases, spheroids were subjected to an irradiance of 5 mW cm-2 for a range of
times required to deliver radiant exposures ranging from 0.5 to 3.0 J cm-2 .

All

irradiations were performed at 37 o C in a temperature controlled incubator. This was
accomplished by inserting the laser-coupled optical fiber through a small aperture located
at the top of the incubator.
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Following light exposure, 16 spheroids from each dish were placed into separate
wells of an agarose coated Costar 48-well plate containing 750 µL of DMEM. Spheroid
growth kinetics were monitored by recording two orthogonal diameters of each spheroid
using a microscope with a calibrated eyepiece micrometer. Spheroid growth was
measured 24 h after treatment and then twice a week over a 29-day period. After each
measurement, 400 µL of DMEM was removed and replaced with 400 µl of fresh DMEM
to provide the spheroids with adequate nutrients.

2.4 Hyperthermia
The 35 mm dishes containing medium and spheroids were placed in a temperature
controlled incubator for 40-50 min. at temperatures ranging from 40o to 50o C. In the case
of the combined treatments (PDT + HT; PCI + HT), spheroids were placed in the
incubator 40 min. prior to light irradiation. Irradiances and radiant exposures were
identical to those described previously. Following treatment, spheroids were placed in a
48-well plate and monitored as previously described. In all cases, the temperature of the
incubator was monitored using a standard laboratory thermometer.

2.5 Statistical Analysis
All data were analyzed and graphed using Microsoft Excel. The two orthogonal
diameter averages were used to calculate the average diameter of the spheroids. Each
experiment included around 16 spheroids per group and was repeated 2-3 times and the
average volume was calculated (V = 4/3 πr3 ). Standard errors were used throughout to
calculate the error bars.
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The degree of interaction between PCI and hyperthermia was evaluated according
to the method of Drewinko et al. (1976). In this scheme the degree of interaction is given
by

(1)
where SFPCI and SFHT represent the surviving fractions following PCI and hyperthermia,
respectively, and SFPCI+HT is the surviving fraction after combined treatments. In this
analysis, α = 1 indicates an additive effect (or absence of any effect), α > 1 indicates a
synergistic effect and α < 1 indicates an antagonistic effect.
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CHAPTER 3
RESULTS

3.1

Radiant exposure of 0.5 J cm-2

3.1.1

37˚C and 50˚C

Based on results from previous in vitro PCI studies, an initial radiant exposure of
0.5 J cm-2 was chosen. The purpose of the initial set of experiments was to: (1) evaluate
the efficacy of very low light exposures, and (2) determine the hyperthermic threshold for
this particular in vitro model. In order to avoid data clutter, the three control curves at
physiological temperature have been plotted in Figure 10. The control groups show
similar growth kinetics over the 29-day observation period. At the time of irradiation (day
0), spheroid diameters ranged from 350-400 µm. ACBT spheroids typically reach a
growth plateau at diameters ranging from 1100-1500 µm which, in these studies,
occurred approximately four weeks following irradiation, thus providing the rationale for
the 29-day observation period.
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Spheroid Volume vs. Time After
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Figure 10. Average spheroid volume over a 29-day period at 37˚C for control groups.
The true control group (no treatment) is denoted by Control, while Dark Control and
BLM represent spheroids incubated in 1 µg ml-1 AlPcS2a and 0.25 µg ml-1 BLM,
respectively.

The data in Figure 11 show complete growth inhibition of all spheroids (control and
treatment groups) subjected to 50 o C for 50 min. Clearly, lower temperatures must be
chosen. No significant differences in growth kinetics between the PCI and PDT groups
were observed at 37 o C suggesting that a radiant exposure of 0.5 J cm-2 was too low.
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Figure 11. Average spheroid volume over a 29-day period at 37and 50˚C.
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40˚C and 45˚C

3.1.2

Spheroid Volume vs. Time After Treatment
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Figure 12. Average spheroid volume over a 29-day period for control groups at 40 and
45˚C.

At temperatures of 45o C, all controls showed significant growth inhibition
compared to spheroids subjected to 40 o C (Figure 12). These results suggest that the
threshold for complete heat- induced cell death occurs somewhere between 40 and 45o C.
As illustrated in Figure 13, no significant differences were observed between the PDT
and PCI groups at 40 o C suggesting that a higher radiant exposure is required. Not
surprisingly, high temperature PDT and PCI resulted in complete growth inhibition.
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Figure 13. Average spheroid volume over a 29-day period at 40˚C and 45˚C.

3.1.3

42˚C
The data in Figure 14 show that spheroids in both treatment and control groups

were growing throughout the observation period. No significant growth differences were
observed between spheroids in the two treatment groups and between spheroids in the
control and treatment groups. Again, this is highly suggestive of inadequate light
exposure levels. The data in Figures 12-14 show that the threshold for complete heatinduced cell death occurs somewhere between 42 and 45 o C. For this reason, a
temperature of 42o C was chosen for the majority of studies presented in this work.

27
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Figure 14. Average spheroid volume over a 29-day period at 42˚C.

Radiant exposure of 1.0 J cm-2

3.2

Spheroid Volume vs. Time After Treatment
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Figure 15. Average spheroid volume over a 29-day period for 1J cm-2 at 37˚C and 42˚C.
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As shown in Figure 15, radiant exposures of 1.0 J cm-2 failed to produce
significant differences in the growth kinetics of spheroids subjected to PCI at the two
temperatures investigated. Even at this low light level, significant growth differences
were observed between PCI- and PDT-treated spheroids at both temperatures. This
suggests that the observed effect is not attributable to PDT.

3.3 Radiant exposure of 1.5 J cm-2
PCI and PDT at 40 o C resulted in a statistically significant reduction in survival
compared to controls (Figure 16). At 37 o C, neither treatment was effective, resulting in
100% survival (data not shown). The alpha coefficient (from equation 1) was found to be
1.4 suggesting a relatively low degree of synergism between 1.5 J PCI and 40 o C.
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Figure 16. The percentage of viable spheroids over a four-week period at 40˚C.
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Spheroid Volume vs. Time After Treatment
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Figure 17. Average spheroid volume over a 29-day period at 1.5 J cm-2 for 37 and 40˚C.

The data in Figure 17 show that PDT and PCI at 1.5 J cm-2 were more effective
than treatments at the lower light levels. For both temperatures investigated, PCI induced
greater growth inhibition than PDT. Both PDT and PCI were more effective at the higher
temperature thus illustrating the therapeutic advantage conferred by hyperthermia. The
effectiveness of combined PCI and hyperthermia at 1.5 J cm-2 can be appreciated by
comparing the final spheroid volume (ca. 0.5 mm3 ) to the final volume obtained for the
combined treatments at 1.0 J cm-2 (ca. 0.8 mm3 : Figure 15).
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3.4 Radiant exposure of 2.5 J cm-2

% Spheroids Viable
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Figure 18. The percentage of viable spheroids over four weeks for 37˚C and 42˚C at 2.5 J
cm-2 . The Dark/BLM Control group represents spheroids incubated in AlPcS 2a for 18 h
followed by a 4 h incubation in bleomycin (no light treatment).

PDT and PCI treatments at a radiant exposure of 2.5 J cm-2 resulted in spheroid
toxicity significantly higher than observed at the lower light levels. This was particularly
the case for the PCI treatments where survivals of approximately 43 and 10 % were
observed at temperatures of 37 and 42o C, respectively (Figure 18). The α coefficient (4.3)
suggests a significant degree of synergism between PCI and hyperthermia (42 o C) at this
radiant exposure. The enhanced efficacy at 2.5 J cm-2 is also evident from the growth
kinetics data in Figures 19 and 20. Of particular relevance is the combined PCI –
hyperthermia data in Figure 20 showing almost complete spheroid growth inhibition as
evidenced from the mean spheroid volume at the end of the observation period (0.2
mm3 ).
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Figure 19. Average spheroid volume over a 29 day period for 37˚C at 2.5J cm-2 .
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Figure 20. Average spheroid volume over a 29-day period for 42 ˚C at 2.5 J cm-2 .
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Radiant exposure of 3 J cm-2

3.5

Complete growth inhibition was observed in all treatment groups, even at
physiological temperatures (37˚C; Figure 21). The data suggest that this light level was
too high.
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Figure 21. Average spheroid volume over a 29-day period for 37, 40 and 42 ˚C at 3J cm2

.
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CHAPTER 4

DISCUSSION

PCI is a specialized application of PDT that may be used to enhance the delivery
of macromolecules including chemotherapeutic agents such as bleomycin. This
therapeutic modality is appealing for a number of reasons including: (1) the lack of size
restrictions on the therapeutic molecules to be delivered, (2) high site specificity which
confines the biological effect to light- illuminated volumes thus minimizing side effects of
the drug, (3) increased therapeutic efficacy of a wide range of macromolecules allowing
for the possibility of lower drug doses resulting in decreased morbidity, (4) high
suitability for combination with other strategies for targeted drug delivery, thereby
increasing the potential for further therapeutic improvements [Berg 1999; Dietze 2005;
Selbo 2001; Selbo 2010; Weyergang 2011].
Although PCI has been investigated in a variety of cancer models, the particular
emphasis of this thesis was the treatment of high grade gliomas such as GBM. These
tumors pose a significant therapeutic challenge: due to their diffuse and infiltrative
nature, complete surgical resection is virtually impossible. The propensity of glioma cells
to migrate along white matter tracts suggests that a cure is possible only if these
migratory cells can be eradicated. The observation that 80% of GBMs recur within 2 cm
of the resection cavity [Wallner 1989] suggests that the development of local therapies
may prove to be an effective strategy for the eradication of glioma cells in the resection
margin, or brain-adjacent-to-tumor (BAT). Unfortunately, the delivery of therapeutic
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agents to the BAT is complicated by variations in the patency of the BBB which is leaky
in some regions and intact in others [Madsen 2010]. The BBB controls the passage of
blood-borne agents into the central nervous system and, as such, it plays a vital role in
protecting the brain against pathogens. Although this protective mechanism is essential
for normal brain function, it also poses a significant hindrance to the entry of drugs into
the brain. The protective function of the BBB is especially problematic for the treatment
of infiltrating gliomas. Although surgery is used to remove gross tumor, standard
adjuvant therapies consisting of radiation and chemotherapy have proven inadequate for
eradicating infiltrating cells in the BAT. In the case of chemotherapeutic drugs, this is
due to their inability to penetrate the intact BBB. Therefore, elimination of glioma cells in
the BAT is unlikely to be accomplished until methods are developed to: (1) deliver drugs
or carriers across the BBB at selected sites, or (2) selectively disrupt the BBB [Madsen
2010].
Selective disruption of the BBB by either PDT or PCI may prove useful for
enhancing the delivery of therapeutic agents for the treatment of a variety of brain
diseases including cancer. Localized opening of the BBB has been accomplished using a
number of techniques including ultrasound [Vykhodtseva 2008] and laser-based
approaches such as PDT [Hirschberg 2008] and PCI [Hirschberg 2009]. These methods
are appealing due to the highly localized nature of the BBB disruption: in contrast to the
use of hyperosmolar solutions, the BBB is only disrupted at sites subjected to sufficient
laser power densities which can be controlled by the user to coincide with the location of
the pathology. Through careful choice of beam parameters, the targeted volume can be as
small as a few mm3 . Of particular interest are observations showing that these highly
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focused approaches do not cause permanent damage to the BBB, as long as incident
power densities remain below threshold levels [Hirschberg 2009]. Under these
conditions, the BBB may remain open for relatively long periods of time thus facilitating
multi- fractionated drug delivery.
Selective disruption of the BBB via PCI-mediated delivery of Clostridium
perfringens epsilon prototoxin (Clp) was recently demonstrated in Fischer rats
[Hirschberg 2009]. Clp was chosen due to the ability of active toxin to cause widespread
and reversible opening of the BBB [Worthington 1975; Nagahama 1991; J. DorcaArevalo 2008]. Following systemic administration, Clp prototoxin is converted to active
toxin via proteolytic cleavage. The results demonstrated that Clp-PCI was capable of
causing localized BBB disruption at very low light fluences (1 J). Based on magnetic
resonance images, maximum BBB opening occurred 3 days following PCI and pathology
analyses revealed no permanent BBB damage at these low light levels.
In a follow-on study, using an orthotopic brain tumor model consisting of F98
glioma cells in Fischer rats, newly implanted tumor cells were used to mimic the
characteristics of infiltrating cells in the resection margin usually found following
surgical removal of gross tumor [Madsen 2006]. PDT- or PCI- localized BBB opening
was performed 24 h following cell inoculation. This is an insufficient time to allow for
the development of bulk tumor and BBB degradation, but long enough for the cells
(doubling time of approximately 18 h) to form small, sequestered, micro-clusters which
are protected by an intact BBB. The survival of animals implanted with F98 tumor cells
was significantly extended following BLM chemotherapy with PCI-mediated BBB
opening compared to controls that received chemotherapy only.

36

As has been shown, the BBB presents a significant obstacle to the delivery of
chemotherapeutic agents, such as bleomycin, to glioma cells residing in the BAT.
Endosomal entrapment is another factor limiting the efficacy of bleomycin and it was this
problem that was addressed in this thesis. PCI- mediated delivery of bleomycin has been
investigated in glioma spheroids [Mathews (in press)] and the results are in qualitative
agreement with the findings of this work, i.e., at sufficient radiant exposures (1.5 J cm-2 )
PCI enhances the efficacy of bleomycin as demonstrated by decreased spheroid survival
and reduced growth kinetics compared to PDT controls. In the previous study, PCI was
examined at relatively low light levels (≤ 1.5 J cm-2 ) and all studies were performed at
physiological temperatures (37o C). The studies performed in this thesis extend the
previous work by examining the effects of higher light doses and, most importantly, the
combination of PCI and hyperthermia.
The exact hyperthermic threshold, i.e., the temperature resulting in a significant
diminution in spheroid survival was somewhat difficult to ascertain due to inaccuracies in
the thermoregulatory capabilities of the incubator in which the cells were irradiated.
Based on temperature readings during the exposures, the incubator was deemed accurate
to 1.0 degrees C. Based on the data presented in Figures 12 and 14 all control spheroids
were viable at 42 o C while almost all were dead at 45 o C thus suggesting a threshold close
to 45o . This is in qualitative agreement with the results of Hirschberg et al. [Hirschberg
2004] who observed significant hyperthermia- induced glioma spheroid death at
temperatures between 46 and 49o C. The slight differences between experiments may be
due to differences in spheroid formation techniques (agar overlay method vs.
centrifugation) which produce slight variations in spheroid morphology. From the results
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presented in Figs. 12 and 14, it was decided to use a temperature of 42 o C for the majority
of studies. This has significant clinical relevance since many patients undergoing
hyperthermia or combined hyperthermia therapies are treated at this temperature. In
future studies, the use of calibrated thermocouples immersed directly in the cell medium
would be a more accurate method of determining the temperature compared to the
technique used in the present work, i.e., the measurement of air temperature using
thermometers.
Of particular relevance are the results showing that hyperthermia can enhance the
effects of PCI-mediated delivery of bleomycin (Figs. 16-18, 20). The degree of
interaction between the two modalities was found to be critically dependent on light dose:
no effect was observed at radiant exposures below 1.5 J cm-2 , while low and high degrees
of synergism were observed at 1.5 and 2.5 J cm-2 , respectively. This is the first
observation of a synergistic interaction between PCI and hyperthermia.
Although the mechanism of synergism between PCI and hyperthermia is
unknown, it likely has several components. For instance, it might be due, in part, to
thermally- induced inhibition of DNA repair enzymes [Van der Zee 2002]. Bleomycin
produces DNA damage and this damage is likely exacerbated if the function of repair
enzymes is inhibited by hyperthermia. Additionally, hyperthermia is known to cause
damage to cellular membranes [Silva 2011] and, by implication, to endosomal
membranes. Subsequently, these heat-damaged membranes may be more susceptible to
the effects of PCI resulting in an enhanced release of bleomycin.

38

CHAPTER 5

CONCLUSIONS

The overall objective of the proposed work was to determine whether
hyperthermia increases the efficacy of PCI-mediated delivery of bleomycin in an in vitro
model consisting of human glioma spheroids. The results show that hyperthermia and
PCI interact in a synergistic manner over a very narrow range of light and temperature
levels. A temperature of 45 o C resulted in total spheroid death, while all spheroids
subjected to 42 o C survived. Therefore, the hyperthermic threshold was estimated to be
between 42 and 45 o C. This provided the rationale for the temperature range investigated
(40 – 42 o C). No significant differences in growth kinetics and survival were observed
between PCI- and PDT -exposed spheroids at radiant exposures < 1.5 J cm-2 . In contrast,
all PDT and PCI spheroids irradiated with 3.0 J cm-2 died, suggesting that the useful light
range is between 1.5 and 3.0 J cm-2 .
The experiments show that hyperthermia enhanced the PCI- mediated delivery of
bleomycin. A relatively low degree of synergism (α=1.4) was observed between PCI and
hyperthermia at 1.5 J cm-2 and 40 o C, while a high degree of synergism (α=4.3) was
found when the two modalities were combined at a light level of 2.5 J cm-2 and a
temperature of 42 o C. This represents the first observation of a synergistic interaction
between PCI and hyperthermia.
Future experiments should consider a better temperature monitoring technique.
By using a thermocouple immersed directly in the cell solution, the temperature can be
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monitored more accurately.

Additional experiments might also examine radia nt

exposures of 2 J cm-2 to determine if the radiant exposure can be limited further to spare
as many healthy cells as possible. Overall, the results provide the basis for additional in
vivo experiments which could be performed using well established orthotopic rat brain
tumor models.
Other experiments should examine the mechanisms underlying the observed
synergism between the two treatment modalities. One possibility is that hyperthermia
inhibits DNA repair enzymes. It was also postulated that hyperthermia can cause damage
to cellular or endosomal membranes, thus resulting in an enhanced release of bleomycin
in PCI. This could be examined by measuring intracellular concentrations of bleomycin
as a function of temperature. Valuable insight into the mechanisms of synergism might be
gained from studying the mode of cell death (apoptosis vs. necrosis) following combined
treatments. Such studies would be relatively straightforward in the human glioma
spheroid model used in this work.
Finally, the efficacy of hyperthermia and PCI should be investigated in different
types of cancer cell lines in order to determine the overall utility of this combination
therapy. A logical starting point would be to use spheroids since they can be formed from
a wide range of cancer cells.
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APPENDIX

LIST OF EQUATIONS
(1) Drewinko Index (α)
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